Patent Assignment
Reel/Frame 074607/0289
Security Interest
Recorded: 2026-02-04
Pages: 42
Assignor
IN3BIO LTD.
Executed: 2024-09-16
Assignee
WITHERS BERGMAN LLP
430 PARK AVE, 10TH FLOOR, NEW YORK, NEW YORK, 10022
Covered Properties
(21)
Recombinant Proteins and Their Therapeutic Uses
Epidermal Growth Factor Fusion Proteins with Mutant Cholera Toxin B Subunits
Recombinant Proteins and Their Therapeutic Uses
Application:
14/996,553 →
Publication:
US 2016/0207972
Methods and Compositions for Inhibition of Egf/Egfr Pathway in Combination with Tyrosine Kinase Inhibitors
Recombinant Proteins and Their Therapeutic Uses
Methods and Compositions for Inhibition of Egf/Egfr Pathway in Combination with Tyrosine Kinase Inhibitors
Application:
16/356,483 →
Publication:
US 2019/0358320
Methods and Compositions for Inhibition of Egf/Egfr Pathway in Combination with Anaplastic Lymphoma Kinase Inhibitors
Synthetic Proteins and Therapeutic Uses Thereof
Self-Assembling Synthetic Proteins
Methods and Compositions for Inhibition of Egf/Egfr Pathway in Combination with Tyrosine Kinase Inhibitors
Recombinant Proteins and Their Therapeutic Uses
Stabilized Chimeric Synthetic Proteins and Therapeutic Uses Thereof
Application:
17/618,065 →
Publication:
US 2022/0305105
Methods and Compositions for Use of Growth Factor Antibodies in Combination with Non-Tyrosine Targeting Kinase Inhibitors
Application:
17/773,741 →
Publication:
US 2022/0378891
Self-Assembling Synthetic Proteins Comprising Cholera Toxin Beta Subunit
Methods of Using Anti-Egf Antibodies to Augment the Activity of Braf and Kras Inhibitors
Application:
18/704,738 →
Publication:
US 2026/0115267
Methods and Compositions for Inhibition of Egf/Egfr Pathway in Combination with Tyrosine Kinase Inhibitors
Application:
62/160,183 →
Anti-Egf Antibodies and Their Therapeutic Synergistic Effect on Alk and Mek Inhibitors
Application:
62/715,351 →
Anti-Egf Antibodies and Their Therapeutic Synergistic Effect on Alk and Mek Inhibitors
Application:
62/727,056 →
Anti-Egf Antibodies and Their Therapeutic Synergistic Effect on Alk and Mek Inhibitors
Application:
62/748,772 →
Anti-Egf Antibodies and Their Therapeutic Synergistic Effect on Alk and Mek Inhibitors
Application:
62/760,529 →
Anti-Egf Antibodies Generated by Vaccination Significantly Improve the Activity of Kinase Inhibitors in Preclinical Models
Application:
62/822,290 →
Related Assignments
(20)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Feb 4, 2016
From: VERHAMME, DANIEL T.
To: BIOVEN 3 LIMITED
Reel/Frame 037661/0687 →
Assignment of Assignor's Interest
Feb 4, 2016
From: CHARLTON, KEITH ALAN; D'HONDT, ERIK
To: BIOVEN 3 LIMITED
Reel/Frame 037661/0581 →
Assignment of Assignor's Interest
Jun 24, 2016
From: D'HONDT, ERIK; VILA, MIGUEL ÁNGEL MOLINA
To: BIOVEN 3 LIMITED
Reel/Frame 039001/0682 →
Security Interest
Sep 7, 2018
From: BIOVEN 3 LTD.
To: INNOCORP VENTURES SDN. BHD.; HALFMOON BAY CAPITAL LTD
Reel/Frame 046814/0374 →
Assignment of Assignor's Interest
Feb 14, 2019
From: D'HONDT, ERIK; VILA, MIGUEL ÁNGEL MOLINA
To: BIOVEN 3 LIMITED
Reel/Frame 048331/0279 →
Change of Name
Aug 2, 2019
From: BIOVEN 3 LTD.
To: IN3BIO LTD.
Reel/Frame 049940/0607 →
Assignment of Assignor's Interest
Jan 24, 2020
From: D'HONDT, ERIK; CHARLTON, KEITH ALAN
To: BIOVEN 3 LIMITED
Reel/Frame 051695/0675 →
Assignment of Assignor's Interest
Mar 6, 2020
From: D'HONDT, ERIK; MOLINA-VILA, MIGUEL ANGEL
To: IN3BIO LTD.
Reel/Frame 052035/0336 →
Assignment of Assignor's Interest
Mar 6, 2020
From: D'HONDT, ERIK; MOLINA-VILA, MIGUEL ANGEL
To: IN3BIO LTD.
Reel/Frame 052035/0328 →
Assignment of Assignor's Interest
Jun 14, 2021
From: D'HONDT, ERIK; MOLINA VILA, MIGUEL ÁNGEL
To: BIOVEN 3 LIMITED
Reel/Frame 056532/0064 →
Change of Name
Jun 16, 2021
From: BIOVEN 3 LTD.
To: IN3BIO LTD.
Reel/Frame 056563/0438 →
Assignment of Assignor's Interest
Aug 24, 2021
From: CHARLTON, KEITH ALAN; D'HONDT, ERIK
To: BIOVEN 3 LIMITED
Reel/Frame 057267/0275 →
Change of Name
Aug 24, 2021
From: BIOVEN 3 LIMITED
To: IN3BIO LTD.
Reel/Frame 057267/0317 →
Assignment of Assignor's Interest
Sep 16, 2021
From: CHARLTON, KEITH ALAN; D'HONDT, ERIK; VERHAMME, DANIEL T.
To: IN3BIO LTD.
Reel/Frame 057498/0742 →
Assignment of Assignor's Interest
May 23, 2024
From: CHARLTON, KEITH ALAN; D'HONDT, ERIK
To: BIOVEN 3 LIMITED
Reel/Frame 067508/0007 →
Change of Name
May 23, 2024
From: BIOVEN 3 LIMITED
To: IN3BIO LTD.
Reel/Frame 067527/0114 →
Change of Name
Jul 2, 2024
From: BIOVEN 3 LIMITED
To: IN3BIO LTD.
Reel/Frame 067892/0272 →
Assignment of Assignor's Interest
Aug 12, 2024
From: D'HONDT, ERIK; MOLINA-VILA, MIGUEL ÁNGEL
To: IN3BIO LTD.
Reel/Frame 068246/0144 →
Assignment of Assignor's Interest
Feb 18, 2025
From: D'HONDT, ERIK; MOLINA VILA, MIGUEL ÁNGEL
To: IN3BIO LTD.
Reel/Frame 070237/0503 →
Assignment of Assignor's Interest
Sep 3, 2025
From: CHARLTON, KEITH ALAN; D'HONDT, ERIK; VERHAMME, DANIEL T.
To: IN3BIO LTD.
Reel/Frame 072144/0138 →